STAT

STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial

STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trialWorldPing

A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

More coverage: all health news on WorldPing.

Related news

Arizona accuses L’Oréal of concealing cancer risks linked to hair relaxersWorldPing
The Guardian

Arizona accuses L’Oréal of concealing cancer risks linked to hair relaxers

Democratic attorney general seeks damages and penalties in legal action that echoes thousands of similar suits Arizona has sued L’Oréal that the French cosmetics company hid evidence that its hair relaxer products ⁠could cause cancer in women – echoi…

Brief by WorldPing · Original reporting by The Guardian